On Tuesday, Denali Therapeutics Inc (NASDAQ: DNLI) opened higher 7.43% from the last session, before settling in for the closing price of $16.02. Price fluctuations for DNLI have ranged from $10.57 to $24.34 over the past 52 weeks.
During the last 5-year period, the sales drop of Healthcare Sector giant was -4.46%. Company’s average yearly earnings per share was noted -16.43% at the time writing. With a float of $138.96 million, this company’s outstanding shares have now reached $146.63 million.
Denali Therapeutics Inc (DNLI) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Denali Therapeutics Inc is 11.01%, while institutional ownership is 89.38%. The most recent insider transaction that took place on Jan 06 ’26, was worth 284,097. Before that another transaction happened on Jan 06 ’26, when Company’s Officer proposed sale 17,218 for $16.50, making the entire transaction worth $284,097.
Denali Therapeutics Inc (DNLI) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.67 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.85) by 0.18. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.77 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -16.43% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.04% during the next five years compared to -4.46% drop over the previous five years of trading.
Denali Therapeutics Inc (NASDAQ: DNLI) Trading Performance Indicators
Check out the current performance indicators for Denali Therapeutics Inc (DNLI). In the past quarter, the stock posted a quick ratio of 9.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.91, a number that is poised to hit -0.75 in the next quarter and is forecasted to reach -2.84 in one year’s time.
Technical Analysis of Denali Therapeutics Inc (DNLI)
Looking closely at Denali Therapeutics Inc (NASDAQ: DNLI), its last 5-days average volume was 1.52 million, which is a drop from its year-to-date volume of 1.86 million. As of the previous 9 days, the stock’s Stochastic %D was 45.38%.
During the past 100 days, Denali Therapeutics Inc’s (DNLI) raw stochastic average was set at 57.66%, which indicates a significant decrease from 74.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.69 in the past 14 days, which was lower than the 0.84 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.22, while its 200-day Moving Average is $15.11. However, in the short run, Denali Therapeutics Inc’s stock first resistance to watch stands at $17.64. Second resistance stands at $18.07. The third major resistance level sits at $18.89. If the price goes on to break the first support level at $16.39, it is likely to go to the next support level at $15.57. Now, if the price goes above the second support level, the third support stands at $15.14.
Denali Therapeutics Inc (NASDAQ: DNLI) Key Stats
There are currently 146,662K shares outstanding in the company with a market cap of 2.69 billion. Presently, the company’s annual sales total 0 K according to its annual income of -422,770 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -126,900 K.
